Heart Failure Seminar: Focus on Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is estimated to affect some 700,000 Americans. Treatment usually includes the use of non-vasodilating beta-blockers followed by non-dihydropyridine calcium channel blockers if these therapies are not effective. Since the release of the most recent guidelines, mavacamten has been approved, and clinical trial data on emerging therapies including aficamten, ranolazine, and evolving gene therapies have been published. In our commitment to providing education that enhances clinical skills and improves patient outcomes, HFSA has identified a need for education in the selection and utilization of current and emerging therapies for HCM.
The HFSA Heart Failure Seminar: Focus on Hypertrophic Cardiomyopathy (HCM) is part of the educational seminar series, featuring a multidisciplinary panel of experts presenting a case-based program that is designed to provide the most current information on the genetics, pathophysiology, diagnosis, clinical trial data, and optimal use of current and emerging treatment options for the management of patients with HCM.
The Heart Failure Society of America acknowledges Bristol Myers Squibb and Cytokinetics for providing an independent educational grant to support HFSA Heart Failure Seminar: Focus on Hypertrophic Cardiomyopathy (HCM)
November 02, 2023
6:00 PM - 7:30 PM ET | Virtual Livestream
- Review the genetics, pathophysiology, and diagnosis of hypertrophic cardiomyopathy.
- Discuss the clinical trial data and optimal use of current and emerging treatment options for the management of patients with hypertrophic cardiomyopathy.
- Identify advanced treatment options for the management of challenging patients with hypertrophic cardiomyopathy.
This activity is intended for cardiologists, interventional cardiologists, primary care physicians, cardiac surgeons, internists, nurse practitioners, physician assistants, nurses, pharmacists, and other health care providers who care for patients with heart failure.